In the largest study to date of the Arthritis Foundation's Tai Chi program, participants showed improvement in pain, fatigue, stiffness and sense of well-being.
Their ability to reach while maintaining balance also improved, said Leigh Callahan, PhD, the study's lead author, associate professor in the University of North Carolina at Chapel Hill School of Medicine and a member of UNC's Thurston Arthritis Research Center.
"Our study shows that there are significant benefits of the Tai Chi course for individuals with all types of arthritis, including fibromyalgia, rheumatoid arthritis and osteoarthritis," Callahan said. "We found this in both rural and urban settings across a southeastern state and a northeastern state."
Callahan will present these results on Monday, Nov. 8, at the annual scientific meeting of the American College of Rheumatology in Atlanta.
In the study, 354 participants were recruited from 20 sites in North Carolina and New Jersey. They were randomly assigned to two groups. The intervention group received the 8-week, twice-weekly Tai Chi course immediately while the other group was a delayed control group. All participants received baseline and 8-week follow-up evaluations, after which the control group also received the Tai Chi course.
To be eligible for study, participants had to have any type of self-reported, doctor-diagnosed arthritis, be 18 years old or older and able to move independently without assistance. However, they did not have to be able to perform Tai Chi standing. They were eligible for the study if they could perform Tai Chi seated, Callahan said.
Self-reports of pain, fatigue and stiffness and physical function performance measures were collected at baseline and at the eight-week evaluation. Participants were asked questions about their ability to perform activities of daily living, their overall general health and psychosocial measures such as their perceived helplessness and self-efficacy. The physical performance measures recorded were timed chair stands (which are a measure of lower extremity strength), gait speed (both normal and fast) and two measures of balance: a single leg stance and a reach test.
At the end of eight weeks the individuals who had received the intervention showed moderate improvements in pain, fatigue and stiffness. They also had an increased sense of well being, as measured by the psychosocial variables, and they had improved reach or balance, Callahan said.
Study co-authors, all from UNC, are statistician Jack Shreffler, PhD, Betsy Hackney, BS, Kathryn Martin, PhD, and medical student Brian Charnock.
Source: University of North Carolina at Chapel Hill School of Medicine
воскресенье, 31 июля 2011 г.
четверг, 28 июля 2011 г.
New Research Demonstrates Value Of Glyco-Flex(R) For Canine Joint Support
Washington State University
researchers released results from three studies that strongly suggest that
Glyco-Flex III, an animal health product formulated by Vetri-Science
Laboratories of Vermont, is a safe and beneficial option for use in dogs
requiring joint support.
An estimated 14 million dogs suffer from joint problems, which is the
sixth-leading cause for which dog owners seek veterinary treatment for
their pets.
"We're pleased that a respected institution like Washington State
University has expanded the scientific research available on the benefits
of Glyco-Flex," said Dale R. Metz, CEO of FoodScience Corporation, the
parent company of Vetri-Science. "Researchers continue to confirm what
we've known for more than two decades: Glyco-Flex offers an excellent
non-pharmaceutical option for animals in need of joint support."
Steven A. Martinez, DVM, MS, Dipl. ACVS, with the university's College
of Veterinary Medicine, and Jaime A. Yanez, a Ph.D. candidate in the
university's College of Pharmacy, presented the results at an opening
session of the 2007 North American Veterinary Conference (NAVC), one of the
profession's largest continuing education programs serving all veterinary
professionals.
As non-pharmaceutical treatment of joint conditions in humans has grown
in prevalence, veterinary medicine began applying some of the lessons
learned in treating human joint conditions. In 1981, Vetri-Science, a
leader in research and product development of high-quality supplements for
large and small animals, developed Glyco-Flex. Glyco-Flex is a proprietary
health product for dogs, cats and horses containing ingredients clinically
proven to promote joint and connective tissue health.
First study shows improved movement in dogs using Glyco-Flex III
In a randomized, double-blind, cross over design dog study, a stifle
osteoarthritis (OA) model was used to determine if Glyco-Flex III could
reduce cartilage breakdown and help normalize joint function. The results
of the study suggest that Glyco-Flex III may reduce the severity of
cartilage breakdown and synovitis, and help normalize joint function in
dogs with stifle joints affected by OA.
Other studies confirms Glyco-Flex III's anti-inflammatory and
antioxidant properties
In the second WSU study, canine chondrocytes were used in cell culture
experiments to assess the effects of Glyco-Flex III tablets on key markers
of inflammation. Glyco-Flex III tablets showed positive reductions in
nitric oxide (NO), soluble collagen, tumor necrosis factor-alpha, IL-6,
PGE(2) and matrix metalloproteinase-3 (MMP-3), which are key markers of
inflammation.
Thus, Glyco-Flex III appears to reduce cartilage breakdown, inhibit
cytokine- induced NO and PGE(2) production, and reduce proteolytic
breakdown.
In the third WSU study, canine chondrocytes were used in cell culture
experiments to assess the effects of the main active constituents in Glyco-
Flex III on key markers of inflammation. These key ingredients - Perna
canaliculus, glucosamine, MSM, DMG and grape seed extract - showed positive
reductions in NO, soluble collagen, tumor necrosis factor-alpha, IL-6,
PGE(2) and MMP-3, which are key markers of inflammation. They also appear
to reduce cartilage breakdown, inhibit cytokine-induced NO and PGE(2)
production and reduce proteolytic breakdown.
These latter two in vitro studies demonstrate some of the key pathways
and mechanisms by which the main components of Glyco-Flex III may function
in the joint. The results also suggest that Glyco-Flex III and its active
components have anti-inflammatory and antioxidant properties.
Glyco-Flex also tested for safety
The WSU studies bring to 14 the number of Vetri-Science-sponsored
research studies that have been conducted at leading universities and by
independent researchers exploring the safety and benefits of Glyco-Flex.
Studies have been conducted measuring everything from veterinarians'
satisfaction with Glyco- Flex to the documented presence of
anti-inflammatory agents in the supplement.
One in vivo study evaluated Glyco-Flex's safety, even when given to
animals at doses much higher than ordinarily recommended. In this clinical
trial, Glyco-Flex III was fed to a treatment group of dogs for 56 days.
Blood and urine tests performed on the treated dogs were all within the
normal ranges and were consistent between groups in each phase of the
study. The dogs' appetites and weights also were unchanged.
Summaries of all the studies are detailed in a brochure titled
"Glyco-Flex and Its Active Ingredients: Clinical and Research Studies",
which is available from the company or any Vetri-Science Sales
Representative or distributor.
The Glyco-Flex difference
Glyco-Flex contains a unique combination of GlycOmega(TM) (Perna
canaliculus from an exclusive New Zealand source) plus DMG, Glucosamine,
MSM and other active ingredients that have been proven beneficial for dogs
requiring joint support. Significantly, it is the only clinically
researched, Perna-based joint support product available.
Perna canaliculus, commonly known as the New Zealand green-lipped
mussel, is a natural source of glycosaminoglycans (including
chondroitin-4 and -6 sulfates and hyaluronic acid), minerals, amino
acids and omega 3 fatty acids - compounds that can make a significant
contribution to canine mobility and comfort. Only Glyco-Flex products
are formulated with GlycOmega(TM) Perna. Unlike Perna extract-based
products and mussel powders which lack important fatty acids and other
bioactive components (e.g. defatted powders or extracts), in Glyco-Flex
the entire organism is utilized, resulting in higher levels of anti-
inflammatory activity. Moreover, a balanced blend of ingredients is
then available to the patient in the same relative proportions as they
occur in nature.
Dimethylglycine (DMG) is a naturally occurring compound that has been
shown to support joint structure and function. Studies also indicate
that DMG acts as a powerful antioxidant to help promote healthy joints
and connective tissues. Four U.S. patents have been awarded to Vetri-
Science Laboratories based on over twenty years of research into the
properties of DMG.
Glucosamine hydrochloride is an ingredient clinically proven to promote
canine joint health. The glucosamine used in all Glyco-Flex products is
guaranteed to be 99% pure. Every lot is tested for quality to ensure
patients receive the highest quality, human-grade glucosamine available.
Methylsulfonylmethane (MSM) has been demonstrated to provide hip and
joint support. The MSM used in Glyco-Flex products is guaranteed to be
99% pure. Every lot is tested for quality to ensure patients receive the
highest quality, human-grade MSM available.
NOTE:
Glyco-Flex is an animal health product. Vetri-Science does not
purport that Glyco-Flex cures, mitigates, treats or prevents any disease.
The conclusions reached in these studies are the observations of
independent researchers and as such, should not be misconstrued as a claim
made by Vetri- Science regarding the benefits of Glyco-Flex. These studies
were conducted to better understand scientifically how the product and
ingredients work, not to support any claim.
ABOUT VETRI-SCIENCE
For more than 25 years, Vetri-Science Laboratories of Vermont has been
a leader in research and product development of high-quality supplements
for large and small animals. A division of FoodScience Corporation,
Vetri-Science is headquartered in Essex Junction, Vermont, and produces
only the purest, most reliable products to meet the exacting standards of
today's veterinarians as well as dog, cat and horse owners.
Vetri-Science
vetriscience/
researchers released results from three studies that strongly suggest that
Glyco-Flex III, an animal health product formulated by Vetri-Science
Laboratories of Vermont, is a safe and beneficial option for use in dogs
requiring joint support.
An estimated 14 million dogs suffer from joint problems, which is the
sixth-leading cause for which dog owners seek veterinary treatment for
their pets.
"We're pleased that a respected institution like Washington State
University has expanded the scientific research available on the benefits
of Glyco-Flex," said Dale R. Metz, CEO of FoodScience Corporation, the
parent company of Vetri-Science. "Researchers continue to confirm what
we've known for more than two decades: Glyco-Flex offers an excellent
non-pharmaceutical option for animals in need of joint support."
Steven A. Martinez, DVM, MS, Dipl. ACVS, with the university's College
of Veterinary Medicine, and Jaime A. Yanez, a Ph.D. candidate in the
university's College of Pharmacy, presented the results at an opening
session of the 2007 North American Veterinary Conference (NAVC), one of the
profession's largest continuing education programs serving all veterinary
professionals.
As non-pharmaceutical treatment of joint conditions in humans has grown
in prevalence, veterinary medicine began applying some of the lessons
learned in treating human joint conditions. In 1981, Vetri-Science, a
leader in research and product development of high-quality supplements for
large and small animals, developed Glyco-Flex. Glyco-Flex is a proprietary
health product for dogs, cats and horses containing ingredients clinically
proven to promote joint and connective tissue health.
First study shows improved movement in dogs using Glyco-Flex III
In a randomized, double-blind, cross over design dog study, a stifle
osteoarthritis (OA) model was used to determine if Glyco-Flex III could
reduce cartilage breakdown and help normalize joint function. The results
of the study suggest that Glyco-Flex III may reduce the severity of
cartilage breakdown and synovitis, and help normalize joint function in
dogs with stifle joints affected by OA.
Other studies confirms Glyco-Flex III's anti-inflammatory and
antioxidant properties
In the second WSU study, canine chondrocytes were used in cell culture
experiments to assess the effects of Glyco-Flex III tablets on key markers
of inflammation. Glyco-Flex III tablets showed positive reductions in
nitric oxide (NO), soluble collagen, tumor necrosis factor-alpha, IL-6,
PGE(2) and matrix metalloproteinase-3 (MMP-3), which are key markers of
inflammation.
Thus, Glyco-Flex III appears to reduce cartilage breakdown, inhibit
cytokine- induced NO and PGE(2) production, and reduce proteolytic
breakdown.
In the third WSU study, canine chondrocytes were used in cell culture
experiments to assess the effects of the main active constituents in Glyco-
Flex III on key markers of inflammation. These key ingredients - Perna
canaliculus, glucosamine, MSM, DMG and grape seed extract - showed positive
reductions in NO, soluble collagen, tumor necrosis factor-alpha, IL-6,
PGE(2) and MMP-3, which are key markers of inflammation. They also appear
to reduce cartilage breakdown, inhibit cytokine-induced NO and PGE(2)
production and reduce proteolytic breakdown.
These latter two in vitro studies demonstrate some of the key pathways
and mechanisms by which the main components of Glyco-Flex III may function
in the joint. The results also suggest that Glyco-Flex III and its active
components have anti-inflammatory and antioxidant properties.
Glyco-Flex also tested for safety
The WSU studies bring to 14 the number of Vetri-Science-sponsored
research studies that have been conducted at leading universities and by
independent researchers exploring the safety and benefits of Glyco-Flex.
Studies have been conducted measuring everything from veterinarians'
satisfaction with Glyco- Flex to the documented presence of
anti-inflammatory agents in the supplement.
One in vivo study evaluated Glyco-Flex's safety, even when given to
animals at doses much higher than ordinarily recommended. In this clinical
trial, Glyco-Flex III was fed to a treatment group of dogs for 56 days.
Blood and urine tests performed on the treated dogs were all within the
normal ranges and were consistent between groups in each phase of the
study. The dogs' appetites and weights also were unchanged.
Summaries of all the studies are detailed in a brochure titled
"Glyco-Flex and Its Active Ingredients: Clinical and Research Studies",
which is available from the company or any Vetri-Science Sales
Representative or distributor.
The Glyco-Flex difference
Glyco-Flex contains a unique combination of GlycOmega(TM) (Perna
canaliculus from an exclusive New Zealand source) plus DMG, Glucosamine,
MSM and other active ingredients that have been proven beneficial for dogs
requiring joint support. Significantly, it is the only clinically
researched, Perna-based joint support product available.
Perna canaliculus, commonly known as the New Zealand green-lipped
mussel, is a natural source of glycosaminoglycans (including
chondroitin-4 and -6 sulfates and hyaluronic acid), minerals, amino
acids and omega 3 fatty acids - compounds that can make a significant
contribution to canine mobility and comfort. Only Glyco-Flex products
are formulated with GlycOmega(TM) Perna. Unlike Perna extract-based
products and mussel powders which lack important fatty acids and other
bioactive components (e.g. defatted powders or extracts), in Glyco-Flex
the entire organism is utilized, resulting in higher levels of anti-
inflammatory activity. Moreover, a balanced blend of ingredients is
then available to the patient in the same relative proportions as they
occur in nature.
Dimethylglycine (DMG) is a naturally occurring compound that has been
shown to support joint structure and function. Studies also indicate
that DMG acts as a powerful antioxidant to help promote healthy joints
and connective tissues. Four U.S. patents have been awarded to Vetri-
Science Laboratories based on over twenty years of research into the
properties of DMG.
Glucosamine hydrochloride is an ingredient clinically proven to promote
canine joint health. The glucosamine used in all Glyco-Flex products is
guaranteed to be 99% pure. Every lot is tested for quality to ensure
patients receive the highest quality, human-grade glucosamine available.
Methylsulfonylmethane (MSM) has been demonstrated to provide hip and
joint support. The MSM used in Glyco-Flex products is guaranteed to be
99% pure. Every lot is tested for quality to ensure patients receive the
highest quality, human-grade MSM available.
NOTE:
Glyco-Flex is an animal health product. Vetri-Science does not
purport that Glyco-Flex cures, mitigates, treats or prevents any disease.
The conclusions reached in these studies are the observations of
independent researchers and as such, should not be misconstrued as a claim
made by Vetri- Science regarding the benefits of Glyco-Flex. These studies
were conducted to better understand scientifically how the product and
ingredients work, not to support any claim.
ABOUT VETRI-SCIENCE
For more than 25 years, Vetri-Science Laboratories of Vermont has been
a leader in research and product development of high-quality supplements
for large and small animals. A division of FoodScience Corporation,
Vetri-Science is headquartered in Essex Junction, Vermont, and produces
only the purest, most reliable products to meet the exacting standards of
today's veterinarians as well as dog, cat and horse owners.
Vetri-Science
vetriscience/
понедельник, 25 июля 2011 г.
Protein T-Bet's Role In Development Of Inflammatory Arthritis
In a study appearing online on January 12 in advance of print publication in the February 2006 issue of the Journal of Clinical Investigation, Laurie Glimcher and colleagues from the Harvard School of Public Health report an essential role for the protein T-bet in the development of inflammatory arthritis.
This protein could provide an attractive new target for therapy for this painful and debilitating condition. Inflammatory arthritis can result when the body's immune system attacks its own healthy tissue and the protein T-bet is a critical regulator of the function of certain immune cells during this response. In their study, Glimcher et al. found that it is the expression of T-bet by dendritic cells, which once activated interact with T and B cells to initiate and shape the immune response, that is critical to the pathology of inflammatory arthritis.
Mice lacking T-bet had markedly reduced joint inflammation and T-bet-deficient mice without T or B cells were essentially resistant to disease. They also found that transfer of normal dendritic cells that make T-bet, but not T-bet-deficient dendritic cells, into mice unable to make T cells, B cells or T-bet, was able to cause inflammatory arthritis. The study shows that the ability of dendritic cells to secrete proinflammatory molecules and to prime T cells to initiate an immune response is compromised in the absence of T-bet. T-bet could provide an attractive new target for therapy in inflammatory arthritis.
TITLE: Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells
View the PDF of this article at:
the-jci/article.php?id=26631
Brooke Grindlinger
press_releasesthe-jci
Journal of Clinical Investigation
jci
This protein could provide an attractive new target for therapy for this painful and debilitating condition. Inflammatory arthritis can result when the body's immune system attacks its own healthy tissue and the protein T-bet is a critical regulator of the function of certain immune cells during this response. In their study, Glimcher et al. found that it is the expression of T-bet by dendritic cells, which once activated interact with T and B cells to initiate and shape the immune response, that is critical to the pathology of inflammatory arthritis.
Mice lacking T-bet had markedly reduced joint inflammation and T-bet-deficient mice without T or B cells were essentially resistant to disease. They also found that transfer of normal dendritic cells that make T-bet, but not T-bet-deficient dendritic cells, into mice unable to make T cells, B cells or T-bet, was able to cause inflammatory arthritis. The study shows that the ability of dendritic cells to secrete proinflammatory molecules and to prime T cells to initiate an immune response is compromised in the absence of T-bet. T-bet could provide an attractive new target for therapy in inflammatory arthritis.
TITLE: Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells
View the PDF of this article at:
the-jci/article.php?id=26631
Brooke Grindlinger
press_releasesthe-jci
Journal of Clinical Investigation
jci
пятница, 22 июля 2011 г.
Why Don't All Insurance Plans Cover Ankle Replacements When The FDA Has Approved Them?
It's been a decade since the U.S. Food and Drug Administration approved the first total ankle-replacement system for patients with severe ankle arthritis.
But several insurance companies still deny coverage, Loyola University Health System orthopaedic surgeon Dr. Michael Pinzur writes in a FootForum commentary in Foot & Ankle International, the official journal of the American Orthopaedic Foot and Ankle Society.
"It seems curious that the FDA agrees with the [foot and ankle society] that total ankle replacement is a reasonable treatment option . . . while several insurance providers do not find ankle replacement as a reasonable treatment option for ankle arthritis," Pinzur writes in the June issue.
An ankle replacement is an option for certain patients who suffer severe osteoarthritis, rheumatoid arthritis or injury-related arthritis that does not respond to more conservative treatments. In such patients, arthritis has destroyed cartilage, so the ankle joint is bone-on-bone.
An ankle replacement is similar to a knee or hip replacement. An implant is attached to the bottom of the tibia (shinbone) and to the talus (the first large bone of the foot). The smooth plastic surface of the tibial implant rotates on the polished metal surface of the talar implant.
Since approving the first total ankle-replacement system in 1999, the FDA has approved two other systems and given tentative approval to a third system. In 2003, the American Orthopaedic Foot and Ankle Society issued a statement that said a total ankle replacement "is a viable option for the treatment of ankle arthritis." And Medicare routinely covers ankle replacements.
Nevertheless, several insurance companies still deny coverage. They base their decision on a "meta-analysis" that concluded an ankle replacement was not a preferred treatment option. The meta-analysis compiled data from previous studies. It was sponsored by insurance companies and based on studies published in 2002 or earlier, Pinzur wrote.
"Should insurance companies make decisions on what treatments are appropriate and what treatments are deemed experimental?" Pinzur's commentary asks.
Pinzur is a professor in the Department of Orthopaedic Surgery and Rehabilitation at Loyola University Chicago Stritch School of Medicine. He has performed more than 50 ankle replacements.
Source:
Jim Ritter
Loyola University Health System
But several insurance companies still deny coverage, Loyola University Health System orthopaedic surgeon Dr. Michael Pinzur writes in a FootForum commentary in Foot & Ankle International, the official journal of the American Orthopaedic Foot and Ankle Society.
"It seems curious that the FDA agrees with the [foot and ankle society] that total ankle replacement is a reasonable treatment option . . . while several insurance providers do not find ankle replacement as a reasonable treatment option for ankle arthritis," Pinzur writes in the June issue.
An ankle replacement is an option for certain patients who suffer severe osteoarthritis, rheumatoid arthritis or injury-related arthritis that does not respond to more conservative treatments. In such patients, arthritis has destroyed cartilage, so the ankle joint is bone-on-bone.
An ankle replacement is similar to a knee or hip replacement. An implant is attached to the bottom of the tibia (shinbone) and to the talus (the first large bone of the foot). The smooth plastic surface of the tibial implant rotates on the polished metal surface of the talar implant.
Since approving the first total ankle-replacement system in 1999, the FDA has approved two other systems and given tentative approval to a third system. In 2003, the American Orthopaedic Foot and Ankle Society issued a statement that said a total ankle replacement "is a viable option for the treatment of ankle arthritis." And Medicare routinely covers ankle replacements.
Nevertheless, several insurance companies still deny coverage. They base their decision on a "meta-analysis" that concluded an ankle replacement was not a preferred treatment option. The meta-analysis compiled data from previous studies. It was sponsored by insurance companies and based on studies published in 2002 or earlier, Pinzur wrote.
"Should insurance companies make decisions on what treatments are appropriate and what treatments are deemed experimental?" Pinzur's commentary asks.
Pinzur is a professor in the Department of Orthopaedic Surgery and Rehabilitation at Loyola University Chicago Stritch School of Medicine. He has performed more than 50 ankle replacements.
Source:
Jim Ritter
Loyola University Health System
вторник, 19 июля 2011 г.
COX-2 inhibitor increases the risk of heart attack in heart healthy elderly adults
New research published in the on-line version of the Annals of Internal Medicine today, documents an increased risk of
heart attack with one of the COX-2 inhibitors used in elderly adults with no previous history of heart attack--a group
previously considered low-risk.
The study, sponsored by the Canadian Institutes of Health Research (CIHR) and conducted by researchers at the McGill
University Health Centre (MUHC) in Montreal, examined the relationship between the use of all nonsteroidal anti-inflammatory
drugs (NSAIDs) and the risk of heart attack in 113,927 Quebec senior citizens. Only one of these agents, a COX-2 inhibitor
called Vioxx--a new class of NSAIDs--carried a greater risk of heart attack.
"Many believe that COX-2 inhibitors increase the chance of a heart attack in high risk groups, for example people who have
already suffered a heart attack," explains primary author Linda L?vesque, a pharmacist and McGill University PhD candidate in
the Department of Epidemiology and Biostatistics. L?vesque worked with co-author Dr. James Brophy, a cardiologist and
Director of the Technology Assessment Unit (TAU) at the MUHC and Associate Professor of Medicine at McGill University. "This
study demonstrates the overall risk of heart attack is increased 24% for users of Vioxx who have not previously suffered a
heart attack," L?vesque says.
The study also reveals that aspirin use can help offset the damaging effects of Vioxx. "Aspirin mitigates the risk to
individuals," confirms L?vesque. "But only in those on a low dosage of Vioxx."
The study also demonstrates that the increased risk of heart attack is only present while taking the drug. "Past users of
Vioxx were not at increased risk," explains L?vesque. "While the risk more than doubles for those who are taking high doses
of the drug even when using aspirin."
COX-2 inhibitors are commonly used to relieve the pain and inflammation caused by arthritis in the elderly. These drugs are
believed to increase the 'stickiness' of blood platelets--the tiny bodies that assist in blood clot formation. "It is
possible that stickier platelets increase the chance of a blockage forming in a blood vessel of the heart," explains
L?vesque. "This study contributes to the growing body of evidence concerning the cardiac safety of COX-2 inhibitors."
About the McGill University Health Centre (MUHC)
The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation
for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with
the Faculty of Medicine at McGill University--the Montreal Children's, Montreal General, Royal Victoria, and Montreal
Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the
founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care
field, and to contribute to the development of new knowledge.
Ian Popple
ian.popplemuhc.mcgill.ca
514-843-1560
McGill University
View drug information on Vioxx.
heart attack with one of the COX-2 inhibitors used in elderly adults with no previous history of heart attack--a group
previously considered low-risk.
The study, sponsored by the Canadian Institutes of Health Research (CIHR) and conducted by researchers at the McGill
University Health Centre (MUHC) in Montreal, examined the relationship between the use of all nonsteroidal anti-inflammatory
drugs (NSAIDs) and the risk of heart attack in 113,927 Quebec senior citizens. Only one of these agents, a COX-2 inhibitor
called Vioxx--a new class of NSAIDs--carried a greater risk of heart attack.
"Many believe that COX-2 inhibitors increase the chance of a heart attack in high risk groups, for example people who have
already suffered a heart attack," explains primary author Linda L?vesque, a pharmacist and McGill University PhD candidate in
the Department of Epidemiology and Biostatistics. L?vesque worked with co-author Dr. James Brophy, a cardiologist and
Director of the Technology Assessment Unit (TAU) at the MUHC and Associate Professor of Medicine at McGill University. "This
study demonstrates the overall risk of heart attack is increased 24% for users of Vioxx who have not previously suffered a
heart attack," L?vesque says.
The study also reveals that aspirin use can help offset the damaging effects of Vioxx. "Aspirin mitigates the risk to
individuals," confirms L?vesque. "But only in those on a low dosage of Vioxx."
The study also demonstrates that the increased risk of heart attack is only present while taking the drug. "Past users of
Vioxx were not at increased risk," explains L?vesque. "While the risk more than doubles for those who are taking high doses
of the drug even when using aspirin."
COX-2 inhibitors are commonly used to relieve the pain and inflammation caused by arthritis in the elderly. These drugs are
believed to increase the 'stickiness' of blood platelets--the tiny bodies that assist in blood clot formation. "It is
possible that stickier platelets increase the chance of a blockage forming in a blood vessel of the heart," explains
L?vesque. "This study contributes to the growing body of evidence concerning the cardiac safety of COX-2 inhibitors."
About the McGill University Health Centre (MUHC)
The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation
for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with
the Faculty of Medicine at McGill University--the Montreal Children's, Montreal General, Royal Victoria, and Montreal
Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the
founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care
field, and to contribute to the development of new knowledge.
Ian Popple
ian.popplemuhc.mcgill.ca
514-843-1560
McGill University
View drug information on Vioxx.
суббота, 16 июля 2011 г.
Study Reveals Potential For NT-proBNP As A Marker To Predict Cardiovascular Risks From Anti-inflammatory Drugs
Roche has announced the results of a pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting the risk of cardiovascular adverse events (CV-AE) in patients treated with non-steroidal anti-inflammatory drugs of the COX inhibitor class.
Non-steroidal anti-inflammatory drugs (NSAIDs) - for example, acetylsalicylic acid and ibuprofen - are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation pathway. This inhibition provides relief from the symptoms of the inflammation process; for example, fever and pain. These drugs are routinely used to treat patients with osteoarthritis, rheumatoid arthritis and other pathologies associated with inflammation. However, studies with newer NSAIDs such as the selective COX-2 inhibitors (also called coxibs) have resulted in concern that there might be an increase in the risk of heart attack, thrombosis or stroke associated with long-term, high-dosage use of coxibs. Traditional NSAIDs (tNSAIDs) demonstrate comparable risks in observational studies.
Cardiovascular risk could be predicted
A pilot study1 examined whether the risk of CV-AE could be predicted by measuring the NT-proBNP concentration in patients taking anti-inflammatory drugs. Baseline samples were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days. Cardiovascular adverse events - including myocardial infarction, stroke, new or worsening of pre-existing arterial hypertension, congestive heart failure, and several less severe CV events - were monitored and retrospectively related to the use of coxibs, tNSAIDs and glucocorticoids.
NT-proBNP value of 100 ng/L as cut-off
The results of the pilot study showed that NT-proBNP values greater than 100 ng/L could be linked to an increase in the cardiovascular risk. Of the 433 patients, 82 mild-to-serious CV-AE were observed (18.9%) during the 200 days. Most of these events were observed in patients with NT-proBNP concentrations ?‰?100 ng/L. The risk for CV-AE in patients with NT-proBNP values ?‰?100 ng/L was 1.95-fold higher (p
Conclusions
The results of this pilot study confirm the potential value of NT-proBNP for risk stratification. "Based on the result of this study, it appears that patients with values below 100 ng/L of NT-proBNP have a low risk of CV-AE from treatment with anti-inflammatory drugs", supposed Evangelos Giannitsis, Department of Internal Medicine, University Hospital of Heidelberg, Germany - a key investigator of the pilot study.1 When confirmed with additional, larger data sets with more reliable endpoints, monitoring NT-proBNP could provide a promising screening strategy for predicting cardiovascular risk in patients with osteoarthritis, and possibly other pathologies associated with the use of anti-inflammatory drugs. Further studies, however, are necessary. "This study suggests a new, important application that could offer routine screening and monitoring for the risk of cardiovascular adverse events to physicians and patients", Dr. Giannitsis said.
The complete results of the study are available in the publication1 or can be obtained by contacting Roche.
1 Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E. The Concentration of N-Terminal Pro-B-type Natriuretic Peptide Predicts the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial. Clin Chem. May 1, 2008 (electronic publication ahead of print), to be published in July 2008.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at roche.
All trademarks used or mentioned in this release are legally protected by law.
roche
Non-steroidal anti-inflammatory drugs (NSAIDs) - for example, acetylsalicylic acid and ibuprofen - are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation pathway. This inhibition provides relief from the symptoms of the inflammation process; for example, fever and pain. These drugs are routinely used to treat patients with osteoarthritis, rheumatoid arthritis and other pathologies associated with inflammation. However, studies with newer NSAIDs such as the selective COX-2 inhibitors (also called coxibs) have resulted in concern that there might be an increase in the risk of heart attack, thrombosis or stroke associated with long-term, high-dosage use of coxibs. Traditional NSAIDs (tNSAIDs) demonstrate comparable risks in observational studies.
Cardiovascular risk could be predicted
A pilot study1 examined whether the risk of CV-AE could be predicted by measuring the NT-proBNP concentration in patients taking anti-inflammatory drugs. Baseline samples were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days. Cardiovascular adverse events - including myocardial infarction, stroke, new or worsening of pre-existing arterial hypertension, congestive heart failure, and several less severe CV events - were monitored and retrospectively related to the use of coxibs, tNSAIDs and glucocorticoids.
NT-proBNP value of 100 ng/L as cut-off
The results of the pilot study showed that NT-proBNP values greater than 100 ng/L could be linked to an increase in the cardiovascular risk. Of the 433 patients, 82 mild-to-serious CV-AE were observed (18.9%) during the 200 days. Most of these events were observed in patients with NT-proBNP concentrations ?‰?100 ng/L. The risk for CV-AE in patients with NT-proBNP values ?‰?100 ng/L was 1.95-fold higher (p
Conclusions
The results of this pilot study confirm the potential value of NT-proBNP for risk stratification. "Based on the result of this study, it appears that patients with values below 100 ng/L of NT-proBNP have a low risk of CV-AE from treatment with anti-inflammatory drugs", supposed Evangelos Giannitsis, Department of Internal Medicine, University Hospital of Heidelberg, Germany - a key investigator of the pilot study.1 When confirmed with additional, larger data sets with more reliable endpoints, monitoring NT-proBNP could provide a promising screening strategy for predicting cardiovascular risk in patients with osteoarthritis, and possibly other pathologies associated with the use of anti-inflammatory drugs. Further studies, however, are necessary. "This study suggests a new, important application that could offer routine screening and monitoring for the risk of cardiovascular adverse events to physicians and patients", Dr. Giannitsis said.
The complete results of the study are available in the publication1 or can be obtained by contacting Roche.
1 Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E. The Concentration of N-Terminal Pro-B-type Natriuretic Peptide Predicts the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial. Clin Chem. May 1, 2008 (electronic publication ahead of print), to be published in July 2008.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at roche.
All trademarks used or mentioned in this release are legally protected by law.
roche
среда, 13 июля 2011 г.
Toward New Drugs That Turn Genes On And Off
Scientists in Michigan and California are reporting an advance toward development of a new generation of drugs that treat disease by orchestrating how genes in the body produce proteins involved in arthritis, cancer and a range of other disorders. Acting like an "on-off switch," the medications might ratchet up the production of proteins in genes working at abnormally low levels or shut off genes producing an abnormal protein linked to disease. Their report is in the current issue of ACS Chemical Biology, a monthly journal.
In the study, Anna K. Mapp and colleagues discusses molecules that cause genes to be active and churn out proteins - so-called transcriptional activators. That's because they control a key process known as transcription, in which instructions coded in genes produce proteins. Malfunctions in these activators could lead to altered transcription patterns that lead to disease. For example, variations in the tumor suppressor gene p53 are found in more than half of all human cancers.
Mapp describes discovery of a group of molecules that could be used to help scientists better understand transcription. Known as activator artificial transcriptional activation domains, these small molecules mimic natural activators and could provide insights on how mistakes in gene regulation result in various diseases. "Evidence suggests that these small molecules mimic the function and mechanism of their natural counterparts and present a framework for the broader development of small molecule transcriptional switches," Mapp states.
Article:
"Amphipathic Small Molecules Mimic the Binding Mode and Function of Endogenous Transcription Factors"
pubs.acs/stoken/presspac/presspac/full/10.1021/cb900028j
Contact:
Anna K. Mapp, Ph.D.
University of Michigan
Ann Arbor, Mich.
Source:
Michael Woods
American Chemical Society
In the study, Anna K. Mapp and colleagues discusses molecules that cause genes to be active and churn out proteins - so-called transcriptional activators. That's because they control a key process known as transcription, in which instructions coded in genes produce proteins. Malfunctions in these activators could lead to altered transcription patterns that lead to disease. For example, variations in the tumor suppressor gene p53 are found in more than half of all human cancers.
Mapp describes discovery of a group of molecules that could be used to help scientists better understand transcription. Known as activator artificial transcriptional activation domains, these small molecules mimic natural activators and could provide insights on how mistakes in gene regulation result in various diseases. "Evidence suggests that these small molecules mimic the function and mechanism of their natural counterparts and present a framework for the broader development of small molecule transcriptional switches," Mapp states.
Article:
"Amphipathic Small Molecules Mimic the Binding Mode and Function of Endogenous Transcription Factors"
pubs.acs/stoken/presspac/presspac/full/10.1021/cb900028j
Contact:
Anna K. Mapp, Ph.D.
University of Michigan
Ann Arbor, Mich.
Source:
Michael Woods
American Chemical Society
воскресенье, 10 июля 2011 г.
New Data Reveals Actemra Is The First And Only Biologic Drug To Show Superiority Over Current Standard Of Care In Rheumatoid Arthritis
The novel rheumatoid arthritis drug Actemra (tocilizumab) has shown superiority over the current standard of care, methotrexate (MTX), by achieving a greater reduction of signs and symptoms (e.g. swollen and tender joints) at 6 months in patients suffering from rheumatoid arthritis.1 This positive outcome makes Actemra the first and only biologic therapy to have achieved superiority over MTX.
Furthermore, nearly three times as many patients treated with Actemra achieved disease remission (as defined by the globally recognised measure DAS28
Furthermore, nearly three times as many patients treated with Actemra achieved disease remission (as defined by the globally recognised measure DAS28
четверг, 7 июля 2011 г.
People With Knee OA Could Be Just A Few Pounds Away From Relief
Very attainable weight loss goals are sufficient to reduce pain and therefore motivate overweight patients with knee osteoarthritis to keep that weight off, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington, DC.
Weight gain dramatically multiplies the pounds of pressure and loading forces on the knee structure. Because this pressure leads to more wear and tear over time, body weight is considered one of the significant contributors to the onset and progression of knee osteoarthritis. Conversely, weight loss can relieve those realities. However, for the 35,000,000 people, 65 years of age and older, whose quality of life is already compromised by osteoarthritis, the need to make large scale changes in their eating and lifestyle habits can be as overwhelming as the symptoms of the disease itself.
Now, a long-term weight loss program has demonstrated that even modest weight loss contributed to improved quality of life in 30 mildly obese patients, and the resulting reduction in pain was so dramatic as to motivate their keeping the weight off. While participants were generally in their late 50s/early 60s, female and white, the improvements they realized in losing and keeping weight off were consistent despite age, race, sex, education or magnitude of weight loss. On average, the group lost 6.8 kg (15 pounds) over 4 months of weekly meetings focused on diet, exercise and lifestyle changes. After quarterly meetings over the following year, they had regained an average of only 2.5 kg (5.5 pounds). The initial weight loss was associated with reduced body pain levels and a quality of life comparable to healthy adults in the same age bracket. The reduction in body pain then motivated participants to maintain their weight loss.
"For someone who is very overweight, as little as a 15-pound weight loss over 16 weeks can result in decreased discomfort, increased quality of life, and motivation for staying active and healthy," explains Steffany Haaz, Project Director, Johns Hopkins Arthritis Center, Baltimore, Maryland; doctoral candidate, Department of Health, Behavior and Society, Johns Hopkins School of Public Health; and an investigator in the study. "That means just one pound a week translates into significant improvements in comfort and movement."
The American College of Rheumatology is the professional organization for rheumatologists and health professionals who share a dedication to healing, preventing disability and curing arthritis and related rheumatic and musculoskeletal diseases. For more information on the ACR's annual meeting, see rheumatology/annual.
Presentation Number: 2075
Evidence for Reciprocal Relationships Among Pain, Weight Loss, and Long Term Weight Maintenance for Obese Persons with Knee OA
Steffany Haaz, Kevin R. Fontaine, Joan M. Bathon, Susan J. Bartlett. Johns Hopkins University, Baltimore, MD
Background. Knee OA is a common, chronic disease that causes pain, disability and reduced quality of life (QOL).
Purpose. To determine the long-term effects of a comprehensive behavioral weight loss program for overweight patients with knee OA.
Participants. Participants were 30 adults who met ACR criteria for knee OA, reported knee pain on most days and had difficulty with daily activities. Participants were generally (mean ± SD) older (58.2 ± 6.1 yrs), female (80%), mildly obese (BMI 32.6 ± 3.0 kg/m2) and white (81%).
Methods. Participants completed a 16-week behavioral weight loss program of weekly meetings focused on diet, exercise and lifestyle change. For 1 year after the intervention, participants met quarterly to discuss weight maintenance strategies. The SF-36 was administered at baseline, post-intervention, and after 1 year. Changes in QOL were assessed with paired t-tests and linear regression models were used to identify predictors of weight loss, weight maintenance and QOL.
Results. Over 4 months, participants lost an average of 6.8 ± 4.7 kg (p
Weight gain dramatically multiplies the pounds of pressure and loading forces on the knee structure. Because this pressure leads to more wear and tear over time, body weight is considered one of the significant contributors to the onset and progression of knee osteoarthritis. Conversely, weight loss can relieve those realities. However, for the 35,000,000 people, 65 years of age and older, whose quality of life is already compromised by osteoarthritis, the need to make large scale changes in their eating and lifestyle habits can be as overwhelming as the symptoms of the disease itself.
Now, a long-term weight loss program has demonstrated that even modest weight loss contributed to improved quality of life in 30 mildly obese patients, and the resulting reduction in pain was so dramatic as to motivate their keeping the weight off. While participants were generally in their late 50s/early 60s, female and white, the improvements they realized in losing and keeping weight off were consistent despite age, race, sex, education or magnitude of weight loss. On average, the group lost 6.8 kg (15 pounds) over 4 months of weekly meetings focused on diet, exercise and lifestyle changes. After quarterly meetings over the following year, they had regained an average of only 2.5 kg (5.5 pounds). The initial weight loss was associated with reduced body pain levels and a quality of life comparable to healthy adults in the same age bracket. The reduction in body pain then motivated participants to maintain their weight loss.
"For someone who is very overweight, as little as a 15-pound weight loss over 16 weeks can result in decreased discomfort, increased quality of life, and motivation for staying active and healthy," explains Steffany Haaz, Project Director, Johns Hopkins Arthritis Center, Baltimore, Maryland; doctoral candidate, Department of Health, Behavior and Society, Johns Hopkins School of Public Health; and an investigator in the study. "That means just one pound a week translates into significant improvements in comfort and movement."
The American College of Rheumatology is the professional organization for rheumatologists and health professionals who share a dedication to healing, preventing disability and curing arthritis and related rheumatic and musculoskeletal diseases. For more information on the ACR's annual meeting, see rheumatology/annual.
Presentation Number: 2075
Evidence for Reciprocal Relationships Among Pain, Weight Loss, and Long Term Weight Maintenance for Obese Persons with Knee OA
Steffany Haaz, Kevin R. Fontaine, Joan M. Bathon, Susan J. Bartlett. Johns Hopkins University, Baltimore, MD
Background. Knee OA is a common, chronic disease that causes pain, disability and reduced quality of life (QOL).
Purpose. To determine the long-term effects of a comprehensive behavioral weight loss program for overweight patients with knee OA.
Participants. Participants were 30 adults who met ACR criteria for knee OA, reported knee pain on most days and had difficulty with daily activities. Participants were generally (mean ± SD) older (58.2 ± 6.1 yrs), female (80%), mildly obese (BMI 32.6 ± 3.0 kg/m2) and white (81%).
Methods. Participants completed a 16-week behavioral weight loss program of weekly meetings focused on diet, exercise and lifestyle change. For 1 year after the intervention, participants met quarterly to discuss weight maintenance strategies. The SF-36 was administered at baseline, post-intervention, and after 1 year. Changes in QOL were assessed with paired t-tests and linear regression models were used to identify predictors of weight loss, weight maintenance and QOL.
Results. Over 4 months, participants lost an average of 6.8 ± 4.7 kg (p
понедельник, 4 июля 2011 г.
Rheumatoid Arthritis - MorphoSys Announces Completion Of First Dosing In Phase 1 Trial For MOR103 Program
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced the completion of a first dosing regimen in a phase 1 clinical study on healthy volunteers of the HuCAL-derived antibody MOR103 with no adverse events reported. Six healthy volunteers in the first dosing group have been enrolled and received MOR103 injections, three volunteers received placebo. The safety review of the medical data from the lowest dosing group concluded that it was safe to proceed to the second dosing group. The randomized, double-blind, placebo-controlled, single-ascending dose trial will be conducted in approx. 50 healthy volunteers and is being conducted in a Clinical Pharmacology Unit (CPU) in Utrecht, the Netherlands. The trial is scheduled to be finalized in 2008 and final reporting is expected in Q1 2009.
The company's lead development program MOR103 is a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor), being developed in the area of inflammatory diseases, such as rheumatoid arthritis, where current treatment options are inadequate. Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad spectrum of anti-inflammatory therapies. MorphoSys had submitted the clinical trial application in December 2007 and received the approval by the Dutch authorities six weeks later. The study will evaluate the safety and tolerability as well as pharmacokinetics of escalating doses of MOR103.
"We are very pleased to see our first proprietary drug candidate progress according to plan," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Antibodies that neutralize GM-CSF could represent a new generation of medicines that reduce inflammation with greater beneficial effects."
About MorphoSys
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford).
For further information please visit morphosys/
About MOR103 to treat RA
Rheumatoid arthritis (RA) is traditionally considered a chronic, inflammatory autoimmune disorder that causes the immune system to attack the joints and affects in particular a membrane, called synovium, which lines each movable joint. It is a disabling and painful inflammatory condition, which can lead to substantial loss of mobility due to pain and joint destruction. As a systemic disease, RA often affects extra-articular tissues throughout the body including the skin, blood vessels, heart, lungs, and muscles. The disease affects approximately 4-6 million people worldwide. In patients suffering from RA, white blood cells move from the bloodstream into the synovium. Here, these blood cells appear to play an important role in causing the synovial membrane to become inflamed.
The HuCAL-based antibody MOR103 targets GM-CSF as a means to treat inflammatory diseases such as psoriasis, multiple sclerosis (MS), chronic obstructive pulmonary disease (COPD), asthma, and especially RA. The granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates stem cells to produce granulocytes and macrophages, and subsequently activates these differentiated immune cells. GM-CSF is part of the natural immune and inflammatory cascade but has also been identified as an inflammatory mediator in autoimmune disorders like RA leading to an increased production of pro-inflammatory cytokines, chemokines and proteases and thereby ultimately to articular destruction. By neutralizing GM-CSF the HuCAL-based antibody MOR103 reduces undesired proliferation and activation of inflammatory granulocytes and macrophages and intervenes in several pathophysiological pathways.
More information and picture material is available here.
HuCAL(R) and HuCAL GOLD(R) are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
MorphoSys
The company's lead development program MOR103 is a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor), being developed in the area of inflammatory diseases, such as rheumatoid arthritis, where current treatment options are inadequate. Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad spectrum of anti-inflammatory therapies. MorphoSys had submitted the clinical trial application in December 2007 and received the approval by the Dutch authorities six weeks later. The study will evaluate the safety and tolerability as well as pharmacokinetics of escalating doses of MOR103.
"We are very pleased to see our first proprietary drug candidate progress according to plan," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Antibodies that neutralize GM-CSF could represent a new generation of medicines that reduce inflammation with greater beneficial effects."
About MorphoSys
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford).
For further information please visit morphosys/
About MOR103 to treat RA
Rheumatoid arthritis (RA) is traditionally considered a chronic, inflammatory autoimmune disorder that causes the immune system to attack the joints and affects in particular a membrane, called synovium, which lines each movable joint. It is a disabling and painful inflammatory condition, which can lead to substantial loss of mobility due to pain and joint destruction. As a systemic disease, RA often affects extra-articular tissues throughout the body including the skin, blood vessels, heart, lungs, and muscles. The disease affects approximately 4-6 million people worldwide. In patients suffering from RA, white blood cells move from the bloodstream into the synovium. Here, these blood cells appear to play an important role in causing the synovial membrane to become inflamed.
The HuCAL-based antibody MOR103 targets GM-CSF as a means to treat inflammatory diseases such as psoriasis, multiple sclerosis (MS), chronic obstructive pulmonary disease (COPD), asthma, and especially RA. The granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates stem cells to produce granulocytes and macrophages, and subsequently activates these differentiated immune cells. GM-CSF is part of the natural immune and inflammatory cascade but has also been identified as an inflammatory mediator in autoimmune disorders like RA leading to an increased production of pro-inflammatory cytokines, chemokines and proteases and thereby ultimately to articular destruction. By neutralizing GM-CSF the HuCAL-based antibody MOR103 reduces undesired proliferation and activation of inflammatory granulocytes and macrophages and intervenes in several pathophysiological pathways.
More information and picture material is available here.
HuCAL(R) and HuCAL GOLD(R) are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
MorphoSys
пятница, 1 июля 2011 г.
In ACL Knee Reconstruction, Hamstring Grafts Prove More Effective
Patients receiving anterior cruciate ligament (ACL) knee reconstruction with a hamstring tendon graft rather than a knee tendon graft were less likely to suffer from pain and mobility issues15 years after surgery, said researchers presenting a study at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Diego, California.
"While we have seen excellent results in terms of knee symptoms and function with both graft types, comparing the two definitely showed differences, "said Leo Pinczewski, MD, lead researcher and surgeon with the North Sydney Orthopaedic and Sports Medicine Center in Wollstonecraft, Australia. "Patients with a hamstring graft reported less knee pain and discomfort and demonstrated a higher activity level."
Surgeons performing ACL graft surgery aim to eliminate instability and quickly return patients to pre-injury function levels. Since ACL ruptures are relatively common, especially in young athletes, surgical procedures are routinely performed.
This study adds to Pinczewski's most recent work exploring the overall success rate of ACL knee reconstruction in athletes after 15 years. "We know that these surgeries work, but this information helps us determine which approaches can be most effective. Getting athletes back on the field is certainly important, but long term success rates are crucial as well," said Pinczewski.
The study followed 180 knee reconstruction patients, with 90 (48 men and 42 women between the ages of 15-42 years) receiving a patellar tendon (PT) graft and the other 90 (47 men and 43 women between the ages of 13-52 years) receiving a hamstring tendon (HT) graft. After 15 years, 80 percent of the PT group and 73 percent of the HT group were assessed based on their symptoms of pain, swelling and knee mobility.
The HT group demonstrated significantly higher activity levels, with 77 percent performing at least strenuous activities, compared to 62 percent being able to perform strenuous activity in the PT group. In evaluating pain when kneeling, 42 percent of the PT group patients reported moderate or greater pain, while 26 percent of the HT group reported pain. The PT group also showed worse outcomes in tests for motion loss and osteoarthritis.
Reasons for increased osteoarthritis in the hamstring tendon graft were uncertain and recommended for further investigation.
Source:
Lisa Weisenberger
American Orthopaedic Society for Sports Medicine
"While we have seen excellent results in terms of knee symptoms and function with both graft types, comparing the two definitely showed differences, "said Leo Pinczewski, MD, lead researcher and surgeon with the North Sydney Orthopaedic and Sports Medicine Center in Wollstonecraft, Australia. "Patients with a hamstring graft reported less knee pain and discomfort and demonstrated a higher activity level."
Surgeons performing ACL graft surgery aim to eliminate instability and quickly return patients to pre-injury function levels. Since ACL ruptures are relatively common, especially in young athletes, surgical procedures are routinely performed.
This study adds to Pinczewski's most recent work exploring the overall success rate of ACL knee reconstruction in athletes after 15 years. "We know that these surgeries work, but this information helps us determine which approaches can be most effective. Getting athletes back on the field is certainly important, but long term success rates are crucial as well," said Pinczewski.
The study followed 180 knee reconstruction patients, with 90 (48 men and 42 women between the ages of 15-42 years) receiving a patellar tendon (PT) graft and the other 90 (47 men and 43 women between the ages of 13-52 years) receiving a hamstring tendon (HT) graft. After 15 years, 80 percent of the PT group and 73 percent of the HT group were assessed based on their symptoms of pain, swelling and knee mobility.
The HT group demonstrated significantly higher activity levels, with 77 percent performing at least strenuous activities, compared to 62 percent being able to perform strenuous activity in the PT group. In evaluating pain when kneeling, 42 percent of the PT group patients reported moderate or greater pain, while 26 percent of the HT group reported pain. The PT group also showed worse outcomes in tests for motion loss and osteoarthritis.
Reasons for increased osteoarthritis in the hamstring tendon graft were uncertain and recommended for further investigation.
Source:
Lisa Weisenberger
American Orthopaedic Society for Sports Medicine
Подписаться на:
Сообщения (Atom)